ADANIPOWER Over Bought!!!ADANIPOWER cross overbought zone and ADX storng trend keep watch for pullback
if beak Upward then enter the trade
SL use for 2% Rule
Nsenifty
UPL Long OR short...UPL ready to break the trend keep watch and confirmation the trend break then entering the trade. Otherwise do not break the trend TP levels mentioned on the chart...
Disclaimer:
The information contained in this presentation is solely for educational purposes. Does do not constitute investment advice. I may or I may not take the trade.
The risk of trading in securities markets can be substantial. You should carefully consider if engaging in such activity is suitable for your own financial situation.
I am not responsible for any liabilities arising from the result of your market involvement or individual trade activities.
Hope this idea will inspire some of you! Don't forget to hit the like/follow button if you feel like this post deserves it
My Predictive Engine's Intraday call (22-Mar) - HCLTECH - SHORTOff-late I started investigating more on predicting the next candle for the day and seeing enough success by using the patterns of various indicators. Pine scripting in tradingview has helped a lot to automate everything and create necessary signals. Based on the engine's call, tomorrow (22-Mar-2018) will be super "RED" candle for NSE:HCLTECH .
Short Below: 935.0
Target-1: 928.0
Target-2: 923.7
Target-3: 919.3
Stop loss: 942.4
Happy Trading!!!
Yes Bank - Shorting opportunityYes Bank - cmp 310
Target - 235
Stop 330
Weekly chart
1) 30 ema breach with heavy volumes.
2) Currently price consolidating in the form of flag pattern.
3) Price expected to break the flag downwards in expectation of the fact that stock has entered Stage 4.
LUPIN BUY (LONG)Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600
Lupin gets USFDA nod to market pain relief, colonoscopy drugs and also gets FDA approval for generic Percocet tablets .
Lupin recently received FDA approval for generic Suprep Bowel Prep Kit and Suprep kit approval It may add 5% to Lupin’s EPS for FY18 earnings.
In addition the pharma major’s Goa facility has been cleared by the US FDA.
Lupin Result: Revenue grew 26% YoY to INR 44.8b Gross margin was stable QoQ at 71.0%. EBITDA rose 27% YoY to INR 12.2b with margin of 27% . EBITDA margin improvement was primarily driven by strong growth in US sales (+53% YoY, +8% QoQ; despite R&D as % of sales at 12.9%) and forex gain of INR 270m. PAT of INR 6.3b was impacted by 1% due to a high tax rate of 39%.
Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600
Nifty - Can Bears capitalize?* Dumpling Top
* 50% Fib retracement
* Gap at play
* Negative crossover on Stochastic
* RSSI sloping southwards
